This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CYNO Cynosure (CYNO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cynosure Stock (NASDAQ:CYNO) 30 days 90 days 365 days Advanced Chart Get Cynosure alerts:Sign Up Key Stats Today's Range$66.00▼$66.0050-Day Range N/A52-Week Range$39.90▼$66.65VolumeN/AAverage Volume1.24 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women's health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies. Read More Receive CYNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cynosure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYNO Stock News HeadlinesCynosure Lutronic Announces U.S. Clearance of the XERF™ Device, Redefining the Future of Non-Invasive Skin TighteningAugust 18, 2025 | finance.yahoo.comAmerican Express Elects Randal K. Quarles and Noel Wallace to Board of DirectorsJuly 23, 2025 | tmcnet.comBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.September 1 at 2:00 AM | Banyan Hill Publishing (Ad)African stories, films now global cynosure —Tolu AjayiJune 27, 2025 | msn.comAuthorities keep a keen eye on 'Silli tiger' in PTRJune 27, 2025 | msn.comSamantha Ruth Prabhu Dazzles In A Bodycon DressMay 27, 2025 | msn.comTesla's Retail Traders Get Buzzing As Board Reportedly Hunts For New CEO To Replace Elon MuskMay 1, 2025 | msn.comWhy the Eccles family, Dave Checketts are launching a $1.2B private-equity fundApril 30, 2025 | msn.comSee More Headlines CYNO Stock Analysis - Frequently Asked Questions How were Cynosure's earnings last quarter? Cynosure, Inc. (NASDAQ:CYNO) posted its quarterly earnings data on Tuesday, July, 26th. The medical equipment provider reported $0.36 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.07. The business's quarterly revenue was up 31.8% on a year-over-year basis. What other stocks do shareholders of Cynosure own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cynosure investors own include Global Blood Therapeutics (GBT), Hawkins (HWKN), DHT (DHT), NVIDIA (NVDA), Xtrackers California Municipal Bond ETF (CA), Golar LNG Partners (GMLP) and Micron Technology (MU). Company Calendar Last Earnings7/26/2016Today9/01/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:CYNO CIK885306 Webwww.cynosure.com Phone+1-978-2564200FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:CYNO) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and ea...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cynosure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cynosure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.